Increased ASV exposure could arise from the severity of liver disease, which attenuates the hepatotropic disposition of ASV via reductions in CYP3A4-mediated metabolism, OATP transport, and hepatic blood flow [6,10,33]. The gene discussed is SLCO1A2; the disease is liver disorder.